Navigation Links
Folic Acid Doesn't Help the Heart
Date:5/6/2008

ents cardiovascular events," Manson said. "Folic acid supplements should not be used for the express purpose of preventing cardiovascular events."

The supplements do have their uses, Manson was quick to add. Folic acid is known to prevent birth defects that affect a baby's brain and spine. "We strongly recommend that women who might become pregnant take additional folic acid supplements," she said.

Manson used the word "additional," because bread and other grain products in the United States and other developed countries are fortified with folic acid. Natural sources of folic acid include green leafy green vegetables and citrus fruits.

Supplements could be recommended routinely for people in countries where no such fortification is done, said Dr. Eva Lonn, professor of medicine at McMaster University in Hamilton, Ontario, Canada, who wrote an accompanying editorial in the journal.

"But what we have learned from the trials in North America, where folic acid is added to flour products, is that there is no role for homocysteine screening or treatment in cardiovascular disease," Lonn said.

Some studies have indicated that folic acid supplements might protect against Alzheimer's disease, she said. "But they aren't conclusive," she added. "We need randomized trials with hard endpoints."

More information

A woman's guide to folic acid is offered by the U.S. National Women's Health Information Center.



SOURCES: JoAnn E. Manson, M.D., chief of preventive medicine, Brigham and Women's Hospital, Boston; Eva Lonn, M.D., professor of medicine, McMaster University, Hamilton, Ontario, Canada; May 7, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Womens Folic Acid Levels Improving
2. Folic Acid May Help Prevent Premature Birth
3. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
4. Drug for cluster headaches may cause heart problems
5. Use of certain lipid measures not more effective in predicting coronary heart disease
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Urban Smog Tough on Young Adults Hearts
8. Stanford study highlights cost-effective method of lowering heart disease risks
9. Vitamin Es lack of heart benefit linked to dosage
10. Drug That Lowers Resting Heart Rate Being Tested
11. Heart Attack Boosts Diabetes Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 1NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 2NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 3Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 1Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 2Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 3Gene Therapy Brings New Muscle to Monkeys 61251 1
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6